Transcriptome analysis showed a Differential signature between invasive and non-invasive corticotrophinomas

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author ARAUJO, Leonardo Jose Tadeu de FMUSP-HC
LERARIO, Antonio Marcondes FMUSP-HC
CASTRO, Margaret de
MARTINS, Clarissa Silva
BRONSTEIN, Marcello Delano FMUSP-HC
MACHADO, Marcio Carlos FMUSP-HC
TRARBACH, Ericka Barbosa FMUSP-HC
FRAGOSO, Maria Candida Barisson Villares FMUSP-HC
dc.date.issued 2017
dc.identifier.citation FRONTIERS IN ENDOCRINOLOGY, v.8, article ID 55, 12p, 2017
dc.identifier.issn 1664-2392
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/20215
dc.description.abstract ACTH-dependent hypercortisolism caused by a pituitary adenoma [Cushing's disease (CD)] is the most common cause of endogenous Cushing's syndrome. CD is often associated with several morbidities, including hypertension, diabetes, osteoporosis/bone fractures, secondary infections, and increased cardiovascular mortality. While the majority (approximate to 80%) of the corticotrophinomas visible on pituitary magnetic resonance imaging are microadenomas (MICs, <10 mm of diameter), some tumors are macroadenomas (MACs, >= 10 mm) with increased growth potential and invasiveness, exceptionally exhibiting malignant demeanor. In addition, larger and invasive MACs are associated with a significant increased risk of local complications, such as hypopituitarism and visual defects. Given the clinical and molecular heterogeneity of corticotrophinomas, the aim of this study was to investigate the pattern of genetic differential expression between MIC and MAC, including the invasiveness grade as a criterion for categorizing these tumors. In this study, were included tumor samples from patients with clinical, laboratorial, radiological, and histopathological diagnosis of hypercortisolism due to an ACTH-producing pituitary adenoma. Differential gene expression was studied using an Affymetrix microarray platform in 12 corticotrophinomas, classified as non-invasive MIC (n = 4) and MAC (n = 5), and invasive MAC (n = 3), according to modified Hardy criteria. Somatic mutations in USP8 were also investigated, but none of the patients exhibited USP8 variants. Differential expression analysis demonstrated that non-invasive MIC and MAC have a similar genetic signature, while invasive MACs exhibited a differential expression profile. Among the genes differentially expressed, we highlighted CCND2, ZNF676, DAPK1, and TIMP2, and their differential expression was validated through quantitative real-time PCR in another cohort of 15 non-invasive and 3 invasive cortocotrophinomas. We also identified potential biological pathways associated with growth and invasiveness, TGF-beta and G protein signaling pathways, DNA damage response pathway, and pathways associated with focal adhesion. Our study revealed a differential pattern of genetic signature in a subgroup of MAC, supporting a genetic influence on corticotrophinomas in patients with CD.
dc.description.sponsorship · Sao Paulo Research Foundation (FAPESP) [2012/17395-5]
· Technological and Scientific Development National Council (CnPQ) [307022/20129]
dc.language.iso eng
dc.publisher FRONTIERS MEDIA SA
dc.relation.ispartof Frontiers in Endocrinology
dc.rights openAccess
dc.subject Cushing's disease; gene expression; neuroendocrine tumors; microarray; anterior pituitary
dc.subject.other growth-factor receptor-4; tumor-transforming gene; secreting pituitary-adenomas; cell-cycle regulators; cushings-disease; promoter hypermethylation; protein-kinase; pttg expression; size; amplification
dc.title Transcriptome analysis showed a Differential signature between invasive and non-invasive corticotrophinomas
dc.type article
dc.rights.holder Copyright FRONTIERS MEDIA SA
dc.description.group LIM/25
dc.description.group LIM/42
dc.identifier.doi 10.3389/fendo.2017.00055
dc.identifier.pmid 28382019
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author ARAUJO, Leonardo Jose Tadeu de:FM:
hcfmusp.author LERARIO, Antonio Marcondes:HC:ICESP
hcfmusp.author BRONSTEIN, Marcello Delano:HC:ICHC
hcfmusp.author MACHADO, Marcio Carlos:HC:ICHC
hcfmusp.author TRARBACH, Ericka Barbosa:HC:LIM/25
hcfmusp.author FRAGOSO, Maria Candida Barisson Villares:HC:ICHC
hcfmusp.author.external · CASTRO, Margaret de:Univ Sao Paulo, Dept Internal Med, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil
· MARTINS, Clarissa Silva:Univ Sao Paulo, Dept Internal Med, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil
hcfmusp.origem.id 2-s2.0-85017104430
hcfmusp.origem.id WOS:000397148300001
hcfmusp.publisher.city LAUSANNE
hcfmusp.publisher.country SWITZERLAND
hcfmusp.relation.reference · Asa SL, 2009, ANNU REV PATHOL-MECH, V4, P97, DOI 10.1146/annurev.pathol.4.110807.092259
· Bartkova J, 2001, GASTROENTEROLOGY, V120, P1680, DOI 10.1053/gast.2001.24880
· BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
· Betticher DC, 1996, ANN ONCOL, V7, P223
· Brito LP, 2010, 15 SINE S INT NEUR S, P3
· Brito LP, 2010, J CLIN ENDOCR METAB, V95, pE271, DOI 10.1210/jc.2010-0047
· Buschges R, 1999, BRAIN PATHOL, V9, P435
· Castano JP, 2010, ENDOCRINOL NUTR, V57, P2
· Colao A, 1999, J CLIN ENDOCR METAB, V84, P2664, DOI 10.1210/jc.84.8.2664
· Di leva A, 2014, NAT REV ENDOCRINOL, V10, P423, DOI 10.1038/NREND0.2014.64
· Evans CO, 2001, J CLIN ENDOCR METAB, V86, P3097, DOI 10.1210/jc.86.7.3097
· Ezzat S, 2004, MOL ENDOCRINOL, V18, P2543, DOI 10.1210/me.2004-0182
· Ezzat S, 2004, CANCER, V101, P613, DOI 10.1002/cncr.20412
· Ezzat S, 2006, MOL ENDOCRINOL, V20, P2965, DOI 10.1210/me.2006-0223
· Feelders RA, 2012, EUR J ENDOCRINOL, V167, P311, DOI 10.1530/EJE-11-1095
· Filippella M, 2006, CLIN ENDOCRINOL, V65, P536, DOI 10.1111/j.1365-2265.2006.02630.x
· Galland F, 2010, ENDOCR-RELAT CANCER, V17, P361, DOI 10.1677/ERC-10-0018
· Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
· Gonzalez-Gomez P, 2003, ONCOL REP, V10, P1031
· Gultekin GD, 2015, J CLIN NEUROSCI, V22, P1282, DOI 10.1016/j.jocn.2015.02.021
· Hardy J, 1969, Clin Neurosurg, V16, P185
· Heaney A, 2014, J NEURO-ONCOL, V117, P459, DOI 10.1007/s11060-014-1413-6
· Hewedi Iman H, 2011, J Egypt Natl Canc Inst, V23, P171, DOI 10.1016/j.jnci.2011.11.003
· Hoglund M, 1996, BLOOD, V87, P324
· Jiang ZQ, 2010, CHINESE MED J-PEKING, V123, P3455, DOI 10.3760/cma.j.issn.0366-6999.2010.23.015
· Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495
· Klug A, 2010, ANNU REV BIOCHEM, V79, P213, DOI 10.1146/annurev-biochem-010909-095056
· KNOSP E, 1993, NEUROSURGERY, V33, P610
· Ladame S, 2006, BIOCHEMISTRY-US, V45, P1393, DOI 10.1021/bi050229x
· Lee EH, 2014, WORLD NEUROSURG, V81, P563, DOI [10.1016/j.wneu.2013.09.035, 10.1016/j.wneu.2013.09.03]
· Machado MC, 2016, J ENDOCRINOL INVEST, V39, P1401, DOI 10.1007/s40618-016-0504-y
· Mangino M, 2012, HUM MOL GENET, V21, P5385, DOI 10.1093/hmg/dds382
· Martins CS, 2015, J ENDOCRINOL INVEST, V38, P1243, DOI 10.1007/s40618-015-0298-3
· Morris DG, 2005, EUR J ENDOCRINOL, V153, P143, DOI 10.1530/eje.1.01937
· Newell-Price J, 2010, CUSHINGS SYNDROME PA, V1, P21
· Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
· Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
· Romanholi DJC, 2008, CLIN ENDOCRINOL, V69, P117, DOI 10.1111/j.1365-2265.2007.03168.x
· Patronas N, 2003, J CLIN ENDOCR METAB, V88, P1565, DOI 10.1210/jc.2002-021438
· Perez-Rivas LG, 2015, J CLIN ENDOCR METAB, V100, pE997, DOI 10.1210/jc.2015-1453
· Pivonello R, 2007, ARQ BRAS ENDOCRINOL, V51, P1381, DOI 10.1590/S0004-27302007000800025
· Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165
· Qian ZR, 2004, J CLIN ENDOCR METAB, V89, P1904, DOI 10.1210/jc.2003-031489
· Reincke M, 2015, NAT GENET, V47, P31, DOI 10.1038/ng.3166
· Rodier F, 2005, INT J BIOCHEM CELL B, V37, P977, DOI 10.1016/j.biocel.2004.10.012
· Rosas SLB, 2001, CANCER RES, V61, P939
· Rossi D, 2003, BRIT J HAEMATOL, V123, P475, DOI 10.1046/j.1365-2141.2003.04644.x
· Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914
· Salehi F, 2008, ENDOCR-RELAT CANCER, V15, P721, DOI 10.1677/ERC-08-0012
· Seemann N, 2001, J PATHOL, V193, P491, DOI 10.1002/path.833
· Seltzer J, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS14683
· Tani Y, 2010, EUR J ENDOCRINOL, V163, P523, DOI 10.1530/EJE-10-0245
· Wilson CB, 1979, CLIN MANAGEMENT PITU, P335
· Woloschak M, 1996, CANCER RES, V56, P2493
· Xiao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090396
· Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761
dc.description.index PubMed
hcfmusp.citation.scopus 12
hcfmusp.citation.wos 9
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics